Regeneron Therapy Extends Colorectal Cancer Patients’ Lives
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA said an experimental drug used in combination with chemotherapy extended the lives of patients with advanced colorectal cancer in a study. Shares rose as much as 12 percent in extended trading.
The companies plan to seek regulatory approval this year for the drug Zaltrap, also called aflibercept, for use in patients not helped by chemotherapy, Tarrytown, New York-based Regeneron and Paris-based Sanofi said today in a statement. The 1,226-patient study, the third of three usually required for U.S. regulatory approval, compared the drug to a placebo in patients and was aimed at achieving a 20 percent benefit in a statistical measure of survival.